Related Experiment Videos
The metabolic syndrome: a vascular perspective
J T Tamsma1, I M Jazet, E D Beishuizen
1Vascular Medicine, Dept. of General Internal Medicine, Leiden University Medical Center, C1-R45, P.O. Box 9600, 2300 RC Leiden, The Netherlands. jttamsma@lumc.nl
European Journal of Internal Medicine
|September 3, 2005
Summary
Metabolic syndrome (MS) increases cardiovascular risk, raising the likelihood of heart disease and stroke. Lifestyle changes and medical interventions are key to managing MS and improving patient outcomes.
Area of Science:
- Cardiovascular Medicine
- Metabolic Disorders
- Public Health
Background:
- Metabolic syndrome (MS) is a growing public health concern characterized by a cluster of cardiovascular risk factors.
- Current diagnostic criteria include hypertension, elevated waist circumference, impaired fasting glucose, dyslipidemia (high triglycerides, low HDL-cholesterol).
- Increasing prevalence is linked to lifestyle changes, including reduced physical activity and rising obesity rates.
Purpose of the Study:
- To review the current understanding of metabolic syndrome (MS).
- To discuss the associated cardiovascular risks and progression of atherosclerosis.
- To outline current and potential therapeutic strategies for MS management.
Main Methods:
- Review of existing literature on metabolic syndrome.
- Analysis of epidemiological data on prevalence and risk factors.
- Synthesis of evidence on therapeutic lifestyle interventions and medical management.
Main Results:
- MS significantly elevates the risk of coronary heart disease, stroke, and mortality from atherosclerotic causes.
- Patients with MS exhibit accelerated atherosclerosis progression and increased vulnerability to cardiovascular events.
- Therapeutic lifestyle changes (exercise, weight reduction) are the primary treatment; medications like antihypertensives, statins, fibrates, and metformin are indicated.
Conclusions:
- Metabolic syndrome poses a substantial cardiovascular threat, necessitating effective management strategies.
- Further research is crucial for refining risk assessment and optimizing medical interventions, including the role of drugs like thiazolidinediones.
- Addressing lifestyle factors and implementing evidence-based medical therapies are vital for mitigating MS-related cardiovascular morbidity and mortality.